📊 TXG Key Takeaways
Is 10x Genomics, Inc. (TXG) a Good Investment?
10x Genomics exhibits strong operational fundamentals with 69.1% gross margins and $130.1M free cash flow generation, supported by a debt-free balance sheet with $474M cash. However, the company is unprofitable at the operating level and revenue growth of only 5.2% YoY is insufficient to offset operational leverage concerns, requiring demonstrated acceleration in growth or faster progress toward profitability.
Why Buy 10x Genomics, Inc. Stock? TXG Key Strengths
- Exceptional gross margin of 69.1% with 20.2% FCF margin demonstrating operational efficiency and pricing power
- Fortress balance sheet with zero debt, $474M cash, and 4.46x current ratio providing significant financial flexibility and runway
- Improving profitability trend with 76.2% YoY net income improvement and positive $136.1M operating cash flow despite negative operating income
TXG Stock Risks: 10x Genomics, Inc. Investment Risks
- Currently unprofitable with -$61M operating income and negative ROE/ROA, indicating capital is not generating returns
- Revenue growth of 5.2% YoY is inadequate for a biotech/diagnostic company and insufficient to achieve profitability through scale
- High operating expense base relative to revenue suggests cost structure challenges requiring either significant top-line growth or material expense reduction
Key Metrics to Watch
- Operating margin trend and timeline to achieve positive operating income
- Revenue growth rate acceleration above 5% threshold
- Operating expense ratio trend and operational leverage realization as revenue scales
10x Genomics, Inc. (TXG) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 20.2% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 4.46x current ratio provides a solid financial cushion.
TXG Profit Margin, ROE & Profitability Analysis
TXG vs Industrial Sector: How 10x Genomics, Inc. Compares
How 10x Genomics, Inc. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is 10x Genomics, Inc. Stock Overvalued? TXG Valuation Analysis 2026
Based on fundamental analysis, 10x Genomics, Inc. has mixed fundamental signals relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
10x Genomics, Inc. Balance Sheet: TXG Debt, Cash & Liquidity
TXG Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: 10x Genomics, Inc.'s revenue has grown significantly by 31% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.18 indicates the company is currently unprofitable.
TXG Revenue Growth, EPS Growth & YoY Performance
TXG Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $149.0M | -$27.3M | $-0.22 |
| Q2 2025 | $153.1M | $180.0K | $0.00 |
| Q1 2025 | $141.0M | -$34.4M | $-0.28 |
| Q3 2024 | $151.7M | -$35.8M | $-0.30 |
| Q2 2024 | $146.8M | -$37.9M | $-0.32 |
| Q1 2024 | $134.3M | -$50.7M | $-0.44 |
| Q3 2023 | $131.1M | -$41.9M | $-0.37 |
| Q2 2023 | $114.6M | -$42.4M | $-0.53 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
10x Genomics, Inc. Dividends, Buybacks & Capital Allocation
TXG SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for 10x Genomics, Inc. (CIK: 0001770787)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TXG
What is the AI rating for TXG?
10x Genomics, Inc. (TXG) has an AI rating of HOLD with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TXG's key strengths?
Claude: Exceptional gross margin of 69.1% with 20.2% FCF margin demonstrating operational efficiency and pricing power. Fortress balance sheet with zero debt, $474M cash, and 4.46x current ratio providing significant financial flexibility and runway.
What are the risks of investing in TXG?
Claude: Currently unprofitable with -$61M operating income and negative ROE/ROA, indicating capital is not generating returns. Revenue growth of 5.2% YoY is inadequate for a biotech/diagnostic company and insufficient to achieve profitability through scale.
What is TXG's revenue and growth?
10x Genomics, Inc. reported revenue of $642.8M.
Does TXG pay dividends?
10x Genomics, Inc. does not currently pay dividends.
Where can I find TXG SEC filings?
Official SEC filings for 10x Genomics, Inc. (CIK: 0001770787) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TXG's EPS?
10x Genomics, Inc. has a diluted EPS of $-0.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TXG a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, 10x Genomics, Inc. has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TXG stock overvalued or undervalued?
Valuation metrics for TXG: ROE of -5.5% (sector avg: 15%), net margin of -6.8% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy TXG stock in 2026?
Our dual AI analysis gives 10x Genomics, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TXG's free cash flow?
10x Genomics, Inc.'s operating cash flow is $136.1M, with capital expenditures of $5.9M. FCF margin is 20.2%.
How does TXG compare to other Industrial stocks?
Vs Industrial sector averages: Net margin -6.8% (avg: 10%), ROE -5.5% (avg: 15%), current ratio 4.46 (avg: 1.8).